INT29885

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.67
First Reported 1988
Last Reported 2009
Negated 1
Speculated 0
Reported most in Body
Documents 13
Total Number 13
Disease Relevance 12.77
Pain Relevance 0.96

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (GGH) extracellular space (GGH) extracellular region (GGH)
lysosome (GGH)
Anatomy Link Frequency
plasma 1
GGH (Homo sapiens)
Pain Link Frequency Relevance Heat
Sumatriptan 5 99.22 Very High Very High Very High
narcan 7 96.40 Very High Very High Very High
headache 3 89.92 High High
Opioid 2 85.20 High High
agonist 1 84.00 Quite High
Endogenous opioid 1 52.84 Quite High
Pain 8 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Herpes Simplex Virus Infection 567 100.00 Very High Very High Very High
Galactorrhea 3 96.20 Very High Very High Very High
Infection 56 94.92 High High
Pollakiuria 1 94.12 High High
Reprotox - General 3 1 93.48 High High
Reprotox - General 2 7 92.20 High High
Nasal Obstruction 1 90.80 High High
Headache 1 89.92 High High
Disease 105 88.24 High High
Cancer 6 84.84 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
For this analysis, the following definitions were used: "prevalent case" = members who had a GH diagnosis claim between the dates of 1/1/96 and 12/31/96; "active case" = members who had a GH diagnosis claim between the dates of 1/1/96 and 12/31/96, and had a drug claim for treating GH or were treated in the hospital for GH; "incident case" = members who had a GH diagnosis or drug claim in 1996 and no GH claim prior to 1996; "recurrent case" = members who were continuously enrolled in 1996, had a GH diagnosis or drug claim in 1996 and a recurrent claim 15 days or more after the first claim (incident cases excluded).
Gene_expression (claim) of GH associated with herpes simplex virus infection
1) Confidence 0.67 Published 2001 Journal BMC Infect Dis Section Body Doc Link PMC35281 Disease Relevance 1.65 Pain Relevance 0
For this analysis, the following definitions were used: "prevalent case" = members who had a GH diagnosis claim between the dates of 1/1/96 and 12/31/96; "active case" = members who had a GH diagnosis claim between the dates of 1/1/96 and 12/31/96, and had a drug claim for treating GH or were treated in the hospital for GH; "incident case" = members who had a GH diagnosis or drug claim in 1996 and no GH claim prior to 1996; "recurrent case" = members who were continuously enrolled in 1996, had a GH diagnosis or drug claim in 1996 and a recurrent claim 15 days or more after the first claim (incident cases excluded).
Gene_expression (diagnosis) of GH associated with herpes simplex virus infection
2) Confidence 0.67 Published 2001 Journal BMC Infect Dis Section Body Doc Link PMC35281 Disease Relevance 1.80 Pain Relevance 0
For this analysis, the following definitions were used: "prevalent case" = members who had a GH diagnosis claim between the dates of 1/1/96 and 12/31/96; "active case" = members who had a GH diagnosis claim between the dates of 1/1/96 and 12/31/96, and had a drug claim for treating GH or were treated in the hospital for GH; "incident case" = members who had a GH diagnosis or drug claim in 1996 and no GH claim prior to 1996; "recurrent case" = members who were continuously enrolled in 1996, had a GH diagnosis or drug claim in 1996 and a recurrent claim 15 days or more after the first claim (incident cases excluded).
Gene_expression (claim) of GH associated with herpes simplex virus infection
3) Confidence 0.67 Published 2001 Journal BMC Infect Dis Section Body Doc Link PMC35281 Disease Relevance 1.62 Pain Relevance 0
For this analysis, the following definitions were used: "prevalent case" = members who had a GH diagnosis claim between the dates of 1/1/96 and 12/31/96; "active case" = members who had a GH diagnosis claim between the dates of 1/1/96 and 12/31/96, and had a drug claim for treating GH or were treated in the hospital for GH; "incident case" = members who had a GH diagnosis or drug claim in 1996 and no GH claim prior to 1996; "recurrent case" = members who were continuously enrolled in 1996, had a GH diagnosis or drug claim in 1996 and a recurrent claim 15 days or more after the first claim (incident cases excluded).
Gene_expression (treating) of GH associated with herpes simplex virus infection
4) Confidence 0.67 Published 2001 Journal BMC Infect Dis Section Body Doc Link PMC35281 Disease Relevance 1.63 Pain Relevance 0
For this analysis, the following definitions were used: "prevalent case" = members who had a GH diagnosis claim between the dates of 1/1/96 and 12/31/96; "active case" = members who had a GH diagnosis claim between the dates of 1/1/96 and 12/31/96, and had a drug claim for treating GH or were treated in the hospital for GH; "incident case" = members who had a GH diagnosis or drug claim in 1996 and no GH claim prior to 1996; "recurrent case" = members who were continuously enrolled in 1996, had a GH diagnosis or drug claim in 1996 and a recurrent claim 15 days or more after the first claim (incident cases excluded).
Gene_expression (case) of GH associated with herpes simplex virus infection
5) Confidence 0.67 Published 2001 Journal BMC Infect Dis Section Body Doc Link PMC35281 Disease Relevance 1.76 Pain Relevance 0
For this analysis, the following definitions were used: "prevalent case" = members who had a GH diagnosis claim between the dates of 1/1/96 and 12/31/96; "active case" = members who had a GH diagnosis claim between the dates of 1/1/96 and 12/31/96, and had a drug claim for treating GH or were treated in the hospital for GH; "incident case" = members who had a GH diagnosis or drug claim in 1996 and no GH claim prior to 1996; "recurrent case" = members who were continuously enrolled in 1996, had a GH diagnosis or drug claim in 1996 and a recurrent claim 15 days or more after the first claim (incident cases excluded).
Gene_expression (diagnosis) of GH associated with herpes simplex virus infection
6) Confidence 0.67 Published 2001 Journal BMC Infect Dis Section Body Doc Link PMC35281 Disease Relevance 1.67 Pain Relevance 0
Sumatriptan induced a striking increase in plasma GH levels in the younger group, whereas it slightly increased GH secretion in the older group (f = 9.59, p < 0.02).
Gene_expression (levels) of GH in plasma associated with sumatriptan
7) Confidence 0.63 Published 1995 Journal J. Neural Transm. Gen. Sect. Section Abstract Doc Link 8695049 Disease Relevance 0.08 Pain Relevance 0.48
For this analysis, the following definitions were used: "prevalent case" = members who had a GH diagnosis claim between the dates of 1/1/96 and 12/31/96; "active case" = members who had a GH diagnosis claim between the dates of 1/1/96 and 12/31/96, and had a drug claim for treating GH or were treated in the hospital for GH; "incident case" = members who had a GH diagnosis or drug claim in 1996 and no GH claim prior to 1996; "recurrent case" = members who were continuously enrolled in 1996, had a GH diagnosis or drug claim in 1996 and a recurrent claim 15 days or more after the first claim (incident cases excluded).
Neg (no) Gene_expression (claim) of GH associated with herpes simplex virus infection
8) Confidence 0.59 Published 2001 Journal BMC Infect Dis Section Body Doc Link PMC35281 Disease Relevance 1.66 Pain Relevance 0
RESULTS: A total of 13 cases of injection-site lipoatrophy were reported, of which ten were in females and three occurred after the first injection; all cases were independent of PEG-GH dose or IGF1 levels, either basal or under treatment.
Gene_expression (dose) of GH
9) Confidence 0.48 Published 2009 Journal Eur. J. Endocrinol. Section Body Doc Link 19654233 Disease Relevance 0 Pain Relevance 0
Endocrinological evaluation revealed high serum levels of GH and prolactin.
Gene_expression (levels) of GH
10) Confidence 0.41 Published 1988 Journal No Shinkei Geka Section Abstract Doc Link 2849724 Disease Relevance 0.74 Pain Relevance 0.09
The endocrine analysis consisted of the measurement of serum levels of GH, PRL and cortisol.
Gene_expression (levels) of GH
11) Confidence 0.35 Published 2003 Journal Neuro Endocrinol. Lett. Section Body Doc Link 12743532 Disease Relevance 0.16 Pain Relevance 0
These data show that oxytocin is capable of inhibiting the rise in ACTH and cortisol, but not in GH and PRL induced by physical exercise.
Gene_expression (rise) of GH
12) Confidence 0.22 Published 1988 Journal Acta Endocrinol. Section Abstract Doc Link 2847472 Disease Relevance 0 Pain Relevance 0.39
The SF-8 is divided into an 8 dimension health profile (PF, RP, BP, GH, VT, SF, RE, and MH) and 2 summary scores (PCS and MCS).
Gene_expression (divided) of GH
13) Confidence 0.15 Published 2008 Journal Biopsychosoc Med Section Body Doc Link PMC2569038 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox